| Autor: |
Chaturvedi A; Hannover Medical School, Hannover, Germany., Gupta C; Hannover Medical School, Hannover, Germany., Gabdoulline R; Hannover Medical School, Hannover, Germany., Borchert NM; Hannover Medical School, Hannover, Germany., Goparaju R; Hannover Medical School, Hannover, Germany., Kaulfuss S; Bayer AG, Berlin, Germany., Görlich K; Hannover Medical School, Hannover, Germany., Schottmann R; Hannover Medical School, Hannover, Germany., Othman B; Hannover Medical School, Hannover, Germany., Welzenbach J; School of Medicine and University Hospital Bonn., Panknin O; Bayer AG, Berlin, Germany., Wagner M; Bayer AG, Berlin, Germany., Geffers R; Helmholtz Centre for Infection Research, Braunschweig, Germany., Ganser A; Hannover Medical School, Hannover, Germany., Thol F; Hannover Medical School, Hannover, German., Jeffers M; Bayer AG, Whippany, NJ, USA., Haegebarth A; Bayer AG, Berlin, Germany., Heuser M; Hannover Medical School, Hannover, Germany. |
| Abstrakt: |
Mutant IDH1 (mIDH1) inhibitors have shown single-agent activity in relapsed/refractory AML, though most patients eventually relapse. We evaluated the efficacy and molecular mechanism of the combination treatment with azacitidine, which is currently the standard of care in older AML patients, and mIDH1 inhibitor BAY1436032. Both compounds were evaluated in vivo as single agents and in combination with sequential (azacitidine, followed by BAY1436032) or simultaneous application in two human IDH1 mutated AML xenograft models. Combination treatment significantly prolonged survival compared to single agent or control treatment (P<.005). The sequential combination treatment depleted leukemia stem cells (LSC) by 470-fold. Interestingly, the simultaneous combination treatment depleted LSCs by 33,150-fold compared to control mice. This strong synergy is mediated through inhibition of MAPK/ERK and RB/E2F signaling. Our data strongly argues for the concurrent application of mIDH1 inhibitors and azacitidine and predicts improved outcome of this regimen in IDH1 mutated AML patients. |
